These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 28282574)

  • 1. Long-term effectiveness and safety of natalizumab in a Portuguese population.
    Correia I; Batista S; Galego O; Marques IB; Jesus-Ribeiro J; Martins AI; Nunes C; Macário MC; Cunha L; Sousa L
    Int Immunopharmacol; 2017 May; 46():105-111. PubMed ID: 28282574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of natalizumab for the treatment of multiple sclerosis in Portugal: a retrospective study.
    Sousa L; de Sa J; Sa MJ; Cerqueira JJ; Martins-Silva A;
    Rev Neurol; 2014 Nov; 59(9):399-406. PubMed ID: 25342053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter, non-interventional study to evaluate the disease activity in Multiple Sclerosis after withdrawal of Natalizumab in Portugal.
    Ladeira F; Braz L; Salgado P; Vaz S; Leitão L; Félix C; Correia AS; Silva AMD; Salgado V; Ferreira F; Vale J; Sá MJ; Capela C
    Clin Neurol Neurosurg; 2019 Sep; 184():105390. PubMed ID: 31306895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
    Zivadinov R; Hojnacki D; Bergsland N; Kennedy C; Hagemeier J; Melia R; Ramasamy DP; Durfee J; Carl E; Dwyer MG; Weinstock-Guttman B
    Eur J Neurol; 2016 Jun; 23(6):1101-9. PubMed ID: 26998905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
    Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
    Ziemssen T; Gass A; Wuerfel J; Bayas A; Tackenberg B; Limmroth V; Linker R; Mäurer M; Haas J; Stangel M; Meergans M; Harlin O; Hartung HP
    BMC Neurol; 2016 Jul; 16():98. PubMed ID: 27405225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
    Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis.
    Saida T; Hao Q; Kanda M; Tani Y
    BMC Neurol; 2023 Aug; 23(1):311. PubMed ID: 37644415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
    Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Richert ND; Uitdehaag BM; Barkhof F; Killestein J
    Mult Scler; 2016 Aug; 22(9):1174-83. PubMed ID: 26564995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD; McQueen RB; Miravalle A; Corboy JR; Vollmer TL; Nair K
    Am J Manag Care; 2013 Apr; 19(4):278-85. PubMed ID: 23725360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.
    Dong-Si T; Gheuens S; Gangadharan A; Wenten M; Philip J; McIninch J; Datta S; Richert N; Bozic C; Bloomgren G; Richman S; Weber T; Clifford DB
    J Neurovirol; 2015 Dec; 21(6):637-44. PubMed ID: 25771865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
    Lanza Cariccio V; Bramanti P; Mazzon E
    Mult Scler Relat Disord; 2018 Feb; 20():93-99. PubMed ID: 29353737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness of fingolimod in a Portuguese real-world population.
    Correia I; Batista S; Marques IB; Sousa M; Ferreira R; Nunes C; Macário MC; Sousa L
    Mult Scler Relat Disord; 2016 Mar; 6():41-48. PubMed ID: 27063621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML).
    Schneider R; Bellenberg B; Hoepner R; Kolb EM; Ellrichmann G; Haghikia A; Gold R; Lukas C
    PLoS One; 2017; 12(4):e0176415. PubMed ID: 28445498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab in relapsing-remitting multiple sclerosis.
    Outteryck O
    Expert Rev Neurother; 2016 May; 16(5):471-81. PubMed ID: 27008031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
    Hodel J; Darchis C; Outteryck O; Verclytte S; Deramecourt V; Lacour A; Zins M; Pruvo JP; Vermersch P; Leclerc X
    Neurology; 2016 Apr; 86(16):1516-23. PubMed ID: 27009257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High cumulative JC virus seroconversion rate during long-term use of natalizumab.
    Vennegoor A; van Rossum JA; Leurs C; Wattjes MP; Rispens T; Murk JL; Uitdehaag BM; Killestein J
    Eur J Neurol; 2016 Jun; 23(6):1079-85. PubMed ID: 27018481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads.
    Prosperini L; Annovazzi P; Capobianco M; Capra R; Buttari F; Gasperini C; Galgani S; Solaro C; Centonze D; Bertolotto A; Pozzilli C; Ghezzi A
    Mult Scler; 2015 Nov; 21(13):1713-22. PubMed ID: 25698174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study.
    Zanghì A; Gallo A; Avolio C; Capuano R; Lucchini M; Petracca M; Bonavita S; Lanzillo R; Ferraro D; Curti E; Buccafusca M; Callari G; Barone S; Pontillo G; Abbadessa G; Di Francescantonio V; Signoriello E; Lus G; Sola P; Granella F; Valentino P; Mirabella M; Patti F; D'Amico E
    Neurotherapeutics; 2021 Apr; 18(2):1166-1174. PubMed ID: 33844155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.